SYRINX Bioanalytics
SYRINX Bioanalytics is recorded as a service provider in 37 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 37 trials · Latest update first
The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes as add on to once-daily basal insulin with or without metformin
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study was conducted in China, Japan, Serbia, Slovakia, South Africa, and the United States of America.
These findings describe the trial, not the service provider’s performance or responsibility.
A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy
Sponsor Argenx
- Start (EU)
- Not reported
- Latest update
- Estimated end
Master Protocol Full Title: A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 1 Full Title: An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod.
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy.
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)
Sponsor Zealand Pharma A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study was conducted in 12 countries: Austria, Canada, Germany, Hungary, India, Ireland, Japan, Malaysia, Poland, Thailand, the United Kingdom, and the United States.
These findings describe the trial, not the service provider’s performance or responsibility.
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for SYRINX Bioanalytics?
The 2026-10-09 snapshot links SYRINX Bioanalytics to 37 distinct CTIS trials. Recorded services include Laboratory services, Free C2 (Complement Component 2), PD analysis (free C2), Exploratory biomarker testing (sClever-1), among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for SYRINX Bioanalytics?
The most frequently recorded therapeutic areas are Endocrinology, Metabolic Disorders, Immunology, Neurology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to SYRINX Bioanalytics conducted?
The linked trials record locations in 25 countries, including Poland, Spain, Italy, Germany, France. These are trial locations, not confirmed office locations or countries where SYRINX Bioanalytics delivered services.
What can this page tell me about SYRINX Bioanalytics's trial experience?
Browse 37 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under SYRINX Bioanalytics. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- SYRINX Bioanalytics Oy